Sangamo BioSciences gives genome modification patent update

|About: Sangamo Therapeutics, Inc. (SGMO)|By:, SA News Editor

The U.S. Patent Office issues a notice of allowance for a claim covering "core architectural aspects of engineered Transcription Activator-Like Effectors."

Sangamo BioSciences (SGMO) says it expects the architectures "to be broadly adopted and become the industry standard."

The technology can be used to edit gene sequences when used with the company's "proprietary engineered FokI nucleases, or DNA cutting domains." (PR)